132 related articles for article (PubMed ID: 4347041)
1. Serologic evidence for a simian-virus-40-like infection of man.
Shah KV; McCrumb FR; Daniel RW; Ozer HL
J Natl Cancer Inst; 1972 Feb; 48(2):557-61. PubMed ID: 4347041
[No Abstract] [Full Text] [Related]
2. Serologic survey for certain childhood viral infections in Rangoon in 1971.
Ming CK; Thein S; Thaung U; U T; Nwe K; Diwan AR
J Trop Med Hyg; 1974 Nov; 77(11):260-6. PubMed ID: 4377013
[No Abstract] [Full Text] [Related]
3. Incidence of SV-40 virus neutralizing antibodies in sera of laboratory workers.
Horváth LB
Acta Microbiol Acad Sci Hung; 1965; 12(2):201-5. PubMed ID: 4284273
[No Abstract] [Full Text] [Related]
4. Antibodies reacting to Simian virus 40 T antigen in human sera.
Shah KV; Daniel RW; Murphy G
J Natl Cancer Inst; 1973 Aug; 51(2):687-90. PubMed ID: 4358141
[No Abstract] [Full Text] [Related]
5. Poliovirus vaccination during pregnancy, maternal seroconversion to simian virus 40, and risk of childhood cancer.
Engels EA; Chen J; Viscidi RP; Shah KV; Daniel RW; Chatterjee N; Klebanoff MA
Am J Epidemiol; 2004 Aug; 160(4):306-16. PubMed ID: 15286015
[TBL] [Abstract][Full Text] [Related]
6. [Anti SV-40 complement fixing antibodies in the serum of children].
Nigro N; Benso L; Brunet MR
Minerva Pediatr; 1968 Jun; 20(23):1175-83. PubMed ID: 4310973
[No Abstract] [Full Text] [Related]
7. Absence of antibody response to simian virus 40 after inoculation with killed-poliovirus vaccine of mothers of offspring with neurologic tumors.
Rosa FW; Sever JL; Madden DL
N Engl J Med; 1988 Jun; 318(22):1469. PubMed ID: 2835679
[No Abstract] [Full Text] [Related]
8. Evidence for an SV40-related papovavirus infection of man.
Shah KV
Am J Epidemiol; 1972 Mar; 95(3):199-206. PubMed ID: 4334622
[No Abstract] [Full Text] [Related]
9. Visna-maedi in sheep.
Gudnadóttir M
Prog Med Virol; 1974; 18(0):336-49. PubMed ID: 4370615
[No Abstract] [Full Text] [Related]
10. Polyomavirus SV40 infections in Kazakhstan.
Nurgalieva ZZ; Wong C; Zhangabylov AK; Omarbekova ZE; Graham DY; Vilchez RA; Butel JS
J Infect; 2005 Feb; 50(2):142-8. PubMed ID: 15667916
[TBL] [Abstract][Full Text] [Related]
11. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia.
MacCallum FO
Spec Rep Ser Med Res Counc (G B); 1971; 310():72-85. PubMed ID: 4324778
[No Abstract] [Full Text] [Related]
12. Patterns of antibodies to SV40 in children following the last booster with inactivated poliomyelitis vaccines.
Gerber P
Proc Soc Exp Biol Med; 1967; 125(4):1284-7. PubMed ID: 4292481
[No Abstract] [Full Text] [Related]
13. [Counterimmunoelectrophoresis of SV40 and its application in quality control and production of poliovaccine].
Ye M
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Feb; 10(1):64-7. PubMed ID: 2838191
[No Abstract] [Full Text] [Related]
14. [Immunofluorescence diagnosis of viral infections].
Kańtoch M; Litwińska B; Wilczyński J
Przegl Epidemiol; 1990; 44(3):139-48. PubMed ID: 2084795
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to simian virus 40 (SV 40) in human sera.
Hahn EE
Prog Immunobiol Stand; 1967; 3():44-7. PubMed ID: 4314436
[No Abstract] [Full Text] [Related]
16. Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer--a review of the epidemiological evidence.
Strickler HD; Goedert JJ
Dev Biol Stand; 1998; 94():235-44. PubMed ID: 9776245
[No Abstract] [Full Text] [Related]
17. Investigation of human malignant tumors in India for simian virus 40 etiology.
Shah KV
J Natl Cancer Inst; 1969 Jan; 42(1):139-45. PubMed ID: 4303828
[No Abstract] [Full Text] [Related]
18. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
[TBL] [Abstract][Full Text] [Related]
19. Development of antibodies to viral and tumor antigens before tumor induction in Syrian golden hamsters inoculated intravenously at 3 weeks of age with SV40.
Diamandopoulos GT; McLane MF
J Immunol; 1974 Nov; 113(5):1450-6. PubMed ID: 4371208
[No Abstract] [Full Text] [Related]
20. SV40 and SV40-like viruses as possible risk factors.
Geissler E
Arch Geschwulstforsch; 1983; 53(3):217-26. PubMed ID: 6311136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
